Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com
2024-02-13
ASH会议
DUBLIN--(BUSINESS WIRE)--The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering.
This report is a comprehensive evaluation and analysis of the technology, products, and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision-makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, and opportunities for injection devices designed for patient self-administration. Provider organization business managers, healthcare administrators, and investors will also benefit from this study.
Evolution in Therapeutic Care
Several recombinant hematologic growth factors or agonists for their receptors have been produced that are useful in treating anemia, neutropenia, and thrombocytopenia, particularly in patients with end-stage renal disease or aplastic anemia or who have received cancer chemotherapy or a hematopoietic cell transplant.
The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones, and other biological drugs also increase the need for safety and compliance.
What You Will Learn
Provides detailed analysis of injectable hematology growth factors delivery and device strategies, and product development factors.
Assesses key markets, market dynamics, and market demographics.
Analyzes therapeutic demand drivers and evaluates injectable drug products in a number of key therapeutic segments.
Provides market data and forecasts.
Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
Assesses the importance of alliances and partnerships on drug product commercialization.
Evaluates the impact of economic, technology, and regulatory factors
Key Topics Covered:
Hematology Market Dynamics
Competitive Factors
Proliferation of Biological Drugs
Product Manufacturers
Hematology Growth Factors
Devices for Administering Injectable Growth Factors
Device Selection - Stability and Material Issues
Competitive Landscape
Prefilled Syringes
Pen Injectors
Dual Chamber Pens
Emerging Devices
Injectable Hematology Growth Factors - Product Assessment
Abseamed
Accofil
Binocrit
Biograstim
Biopoin
Epoetin Alfa Hexal
Filgrastim Hexal
Fulphila
Granix
NeoRecormon
Nivestim
Retacrit
Udenyca (Coherus BioSciences)
Market Assessment
Hematopoietic Stem Cell Transplant
Neutropenia
Predonation of Autologous Blood
Company Profiles
Companies Mentioned
Medice Arzneimittel
Ratiopharm
Rentscler Biotechnologie
For more information about this report visit https://www.researchandmarkets.com/r/bktosb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。